Study of LY2140023 in Schizophrenia

Update Il y a 4 ans
Reference: NCT00149292

Woman and Man

Extract

Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.


Inclusion criteria

  • Schizophrenia

Links